PMID- 12172693
OWN - NLM
STAT- MEDLINE
DCOM- 20030107
LR  - 20151119
IS  - 0033-3158 (Print)
IS  - 0033-3158 (Linking)
VI  - 162
IP  - 4
DP  - 2002 Aug
TI  - Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in 
      humans.
PG  - 396-405
AB  - RATIONALE: 3,4-Methylenedioxymethamphetamine (MDMA) is a widely used 
      phenethylamine. Reports have described the effects of MDMA in a controlled 
      laboratory setting, but the full range of effects of MDMA in humans is still not 
      completely characterized. OBJECTIVES: To describe the physiological, subjective, 
      and hormonal changes after single doses of MDMA in a laboratory setting and 
      examine relationships between these effects. METHODS: Eight MDMA-experienced 
      volunteers each received placebo, 0.5 mg/kg, and 1.5 mg/kg oral doses of MDMA in 
      a double-blind crossover study. RESULTS: The 1.5 mg/kg dose (comparable to that 
      typically used by most participants) produced significant subjective effects, 
      peaking at about 2 h after dosing, including some effects commonly associated 
      with stimulant drugs, hallucinogens, and entactogens. MDMA significantly 
      increased plasma cortisol, prolactin, and dehydroepiandrosterone (DHEA) levels. 
      Increase in plasma cortisol after the 1.5 mg/kg dose correlated with increased 
      heart rate, rate-pressure product, and drug liking. Rise in DHEA correlated with 
      euphoria. CONCLUSIONS: A typically used dose of MDMA produced effects commonly 
      associated with stimulants and hallucinogens. Subjects liked MDMA. Correlations 
      between cortisol and DHEA levels and some physiological and psychological effects 
      are consistent with animal data suggesting that hormones modulate some responses 
      to drugs of abuse.
FAU - Harris, Debra S
AU  - Harris DS
AD  - Drug Dependence Research Center, Langley Porter Psychiatric Institute, University 
      of California, San Francisco, 401 Parnassus Avenue, San Francisco, CA 94143-0984, 
      USA.
FAU - Baggott, Matthew
AU  - Baggott M
FAU - Mendelson, Jack H
AU  - Mendelson JH
FAU - Mendelson, John E
AU  - Mendelson JE
FAU - Jones, Reese T
AU  - Jones RT
LA  - eng
GR  - 5 MO1 RR-00079/RR/NCRR NIH HHS/United States
GR  - DA00053/DA/NIDA NIH HHS/United States
GR  - DA00064/DA/NIDA NIH HHS/United States
GR  - DA01696/DA/NIDA NIH HHS/United States
GR  - DA12393/DA/NIDA NIH HHS/United States
GR  - DA14528/DA/NIDA NIH HHS/United States
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20020627
PL  - Germany
TA  - Psychopharmacology (Berl)
JT  - Psychopharmacology
JID - 7608025
RN  - 0 (Hallucinogens)
RN  - 0 (Hormones)
RN  - 459AG36T1B (Dehydroepiandrosterone)
RN  - 9002-62-4 (Prolactin)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - WI4X0X7BPJ (Hydrocortisone)
SB  - IM
MH  - Adult
MH  - Analysis of Variance
MH  - Cardiovascular Physiological Phenomena/*drug effects
MH  - Cross-Over Studies
MH  - Dehydroepiandrosterone/blood
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Female
MH  - Hallucinogens/*pharmacology
MH  - Hormones/blood
MH  - Humans
MH  - Hydrocortisone/blood
MH  - Male
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*pharmacology
MH  - Prolactin/blood
MH  - Psychometrics
MH  - Surveys and Questionnaires
MH  - Time Factors
EDAT- 2002/08/13 10:00
MHDA- 2003/01/08 04:00
CRDT- 2002/08/13 10:00
PHST- 2001/11/18 00:00 [received]
PHST- 2002/04/17 00:00 [accepted]
PHST- 2002/08/13 10:00 [pubmed]
PHST- 2003/01/08 04:00 [medline]
PHST- 2002/08/13 10:00 [entrez]
AID - 10.1007/s00213-002-1131-1 [doi]
PST - ppublish
SO  - Psychopharmacology (Berl). 2002 Aug;162(4):396-405. doi: 
      10.1007/s00213-002-1131-1. Epub 2002 Jun 27.